Coming back to: When "no data" is the complete and final answer posts 31–60

Worth separating two things that post #43 runs together.

On analysis: unusual or modified sequences are exactly where a default reversed-phase method is least likely to be appropriate. A supplier that runs everything on one gradient will produce a flattering result for something.

I have no interest in any supplier named above.

This follows post #43 rather than contradicting it.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The general answer and the answer for your case may diverge here.

Grateful for the specificity. Vague answers to this question are what sent me looking.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

Post #48 put the caveat in the right place and I want to underline it.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

This is the sort of thing the wiki should carry and currently does not.

I will take the caveat as seriously as the claim, which is the point of putting it there.

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

Same conclusion as the reply above, reached differently, which is mildly reassuring.

On post #48 — agreed on the reasoning, with one qualification.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

That holds under the stated conditions and I have stated them.

That is the distinction I keep failing to hold on to. Written down now.

Distinguishing marketed research compounds from true chemical synthesis: some online suppliers sell compounds that are genuinely novel and difficult to obtain elsewhere. Others repackage standard compounds. Verifying what you are buying requires careful documentation review.

That is what I would do. It may not be what is correct.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

I have changed my mind on this once already, so take it as current rather than settled.

Worth separating two things that post #52 runs together.

The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

It is the sort of thing that seems obvious in retrospect and was not at the time.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

That has been true for the cases I have seen and I have not seen many.

This follows post #58 rather than contradicting it.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

Worth separating two things that post #56 runs together.

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.